Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02657551 · ClinicalTrials.gov registry record · Phase 2

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

A Phase 2 study of Thyroid Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
8
Enrollment target
2
Study locations

NCT02657551: Active Phase 2 study of Thyroid Cancer, sponsored by Dana-Farber Cancer Institute.

NCT02657551 is a Phase 2 study of Thyroid Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 8 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02657551, a Phase 2 study of Thyroid Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention involved in this study is regorafenib.

Primary Outcome

10-month PFS Rate is the proportion of participants ramaing alive and progression free at 10 months. Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or mor

Conditions Studied

Thyroid Cancer

Interventions

  • DRUG Regorafenib

Study Locations (2)

Connecticut

  • Yale Cancer Center - New Haven

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-01
Est. Completion 2025-12
Phase Phase 2
Dana-Farber Cancer Institute

781 total trials

What the registry record for NCT02657551 still lists

NCT02657551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib is the first listed.

NCT02657551 reports a single indexed study location in Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02657551 about?

NCT02657551 is a clinical study titled "A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer". This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention in...

What is the current status of trial NCT02657551?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-01. Estimated completion is 2025-12.

What conditions does trial NCT02657551 study?

This clinical trial studies the following conditions: Thyroid Cancer.

What interventions are being tested in trial NCT02657551?

The interventions under investigation include: Regorafenib (DRUG).

Who is sponsoring clinical trial NCT02657551?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02657551 being conducted?

This trial has 2 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02657551's enrollment target sits among peer trials

8 46th of 46 higher than 1 of 46 other Thyroid Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02657551, the US trial registry maintained by the National Library of Medicine. NCT02657551 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.